Abstract: Heart failure is a leading cause of death in industrialized nations especially in an aging population. The recent improvements in cardiac revascularization therapy reduced death rates because of myocardial infarction but steadily increased the number of individuals developing cardiac remodeling and heart failure in the future. Conceptual novel approaches entering the clinics to treat cardiac remodeling and heart failure remain scarce. MicroRNAs emerged as powerful and dynamic modifiers of cardiovascular diseases. In this review, the current approaches using microRNAs as novel diagnostic and therapeutic strategies for cardiac remodeling and heart failure are highlighted. Other gene regulatory mechanisms presented include long (>200 bp) noncoding RNAs that function as an additional regulatory machinery of the genome controlling both transcriptional and posttranscriptional events also in the cardiovascular system. ( 
H eart failure (HF) is a leading cause of death in industrialized nations especially in an aging population. The recent improvements in cardiac revascularization therapy reduced death because of myocardial infarction (MI) but steadily increased the number of individuals developing HF after MI. 1 In strong contrast to the therapeutic developments in cardiac revascularization therapy, conceptual novel approaches in the clinics to treat the heart at the wound healing phase and to improve cardiac remodeling processes remain scarce.
In humans, DNA sequences corresponding to proteincoding exons and untranslated regions all together comprise only 1.5% to 2% of the total genome. 2 Recent evidence suggests that the nonprotein coding portion of the genome that was previously thought to be junk may also have functional importance. Numerous studies in the field of RNA research have highlighted a dominating role of microRNAs (miR/ miRNA), a certain class of noncoding RNAs (ncRNAs), in almost every biological process of higher eukaryotes. However, in addition to miRNAs, there exist numerous classes of other ncRNAs, which can be broadly categorized as small ncRNAs and long ncRNAs (lncRNA). Small ncRNAs, in addition to miRNAs, include Piwi-interacting RNAs, small nuclear RNA, small nucleolar RNA, and promoter-associated small RNAs. lncRNAs include long intergenic ncRNAs, long intronic ncRNAs, telomeric ncRNAs transcribed from subtelomeric promoters (telomeric repeat-containing RNA), pseudogene transcripts, circular RNAs, enhancer RNAs, and transcribed ultraconserved regions.
In view of the vast classes of noncoding regulatory RNAs whose role has yet to be explored in pathological conditions, our current knowledge is apparently only in its early beginnings. Thanks to advanced deep sequencing and other analysis technologies, the detection of ncRNAs has been made more easy enabling initiation of in-depth research of the different classes of ncRNAs. So far in the cardiology field mainly the role of a class of ncRNAs, miRNAs, was investigated. A recent breakthrough study identifying a role of a long intergenic ncRNA, Braveheart, in cardiac development 3 underscores the importance of other ncRNAs in heart physiology and diseases.
In this review, we will highlight the role of miRNAs for novel diagnostic and therapeutic strategies for cardiac remodeling and HF. We think that this kind of approach will enter clinical evaluation in cardiovascular diseases in the not too far future. MiRNAs are small endogenous RNA molecules that regulate gene expression by base pairing with complementary sites in messenger RNAs (mRNAs), thereby inducing transcriptional repression or target mRNA degradation. However, miRNAs were not recognized as distinct class of biological regulators until the discovery of let-7 in 2000. 4 Strong sequence conservation of let-7 through broad range of species 5 has provoked researchers to look for similar regulatory molecules in other animals, including flies and mammals, which resulted in identification of numerous regulatory small RNA molecules in different species.
Since the first discovery of a miRNA, lin-4, in worms 20 years ago, 6, 7 there was a tremendous gain in knowledge about the regulation, expression, and function of miRNAs in many biological functions and disease areas, including cardiovascular disease. Because of increasingly large number of miRNAs that have been identified, several databases have been formed (eg, miRBase; http://mirbase.org/), which curate all miRNAs that are identified experimentally or through bioinformatic analyses. 8 The newest release of this database (release 19) has information about >25 000 miRNAs from 193 species and thanks to completed genome projects and advanced sequence analysis tools, the list keeps on increasing.
In this compendium review, we comprehensively summarize the role, function, and diagnostic/therapeutic use of miRNAs in cardiac hypertrophy, remodeling, and failure.
miRNAs During Heart Development and Implications for Cardiac Regeneration
Generally, genes involved in basic important cellular processes avoid miRNA-mediated degradation because of their short 3′ untranslated regions that are specifically depleted of miRNA binding sites. 9 Sometimes, miRNAs mediate gene repression in a tissue-specific manner as a result of mutual exclusiveness of either miRNA or its target mRNA. 10 The central role of miRNAs for heart biology was identified by selective depletion of the miRNA processing enzyme dicer in different stages of development. When Dicer was selectively deleted in cardiac progenitor cells using the promoter of a cardiac-specific transcription factor Nkx2.5-driven Cre recombinase (Nkx2.5-Cre), embryos die at embryonic day 12.5 (E12.5).
11 Deletion of Dicer in postnatal cardiomyocytes of 3-week-old mice resulted in sudden cardiac death within 1 week. 12 Deletion of Dicer in cardiomyocytes of α-myosin heavy chain (α-MHC/Myh6)-Cre line leads to lethality between postnatal days 0 and 4, 13 highlighting the importance of miRNAs in the heart. However, deletion of individual miRNAs, such as miR-1-2, 11 208a, 14 208b, 499, 15 133a-1, and 133a-2, 16 did not show severe phenotypes suggesting that many miRNAs perform redundant functions.
Deep sequence-based miRNA expression analysis has revealed that 18 miRNA families (in the order of abundance: miR-1/206, let-7/98, miR-30, miR-29, miR-26, miR-378, miR-143, miR-24, miR-133, and 9 others) contribute to ≈90% of total miRNAs expressed in the heart. 17 This indicates that either the majority of miRNA-mediated biological processes in the heart are mediated by this small (but more abundant) set of miRNAs or a large number of (but less abundant) miRNAs play important roles irrespective of their expression level. Evidence for the latter notion comes from the fact that silencing of miRNAs that are not abundantly expressed in heart, such as miR-143 and miR-138, in an vertebrate model results in abnormal development of cardiac chambers. 18, 19 Of note, miR-133, which is also specifically expressed in muscle and originates from the same bicistronic transcript as miR-1, is expressed at much lower levels as compared with miR-1, suggesting a post-transcriptional regulation of these miRNAs. Transcription of the miR-1/miR-133 bicistron is regulated by a myogenic transcription factors MyoD, serum response factor, myocyte enhancer factor 2, and Myf5. [20] [21] [22] Homozygous deletion of miR-1-2 results in 50% embryonic lethality. Mutant mice that survive until birth exhibit cardiac arrhythmias and succumb to sudden cardiac death, highlighting the postnatal cardiac function of miR-1.
11 Other heart-specific miRNAs, such as miR-208a, miR-208b, and miR-499, are encoded in the introns of heart-specific genes Myh6, Myh7, and Myh7b, respectively. 23 During development, expression of Myh6 and Myh7 correlates inversely with each other.
In addition to cardiac development, miRNAs have also been found to regulate cardiomyocyte proliferation ( Figure 1A) . In an elegant study, researchers identified that miR-195, a member of miR-15 family, regulates cell-cycle withdrawal of cardiomyocytes at the neonatal stage. 24 The neonatal heart, in contrast to the adult heart, displays remarkable regenerative capacity. 25 In rodents, regenerative capacity of heart ceases at postnatal day 7 (P7), 25 which coincides with loss of proliferative capacity and onset of binucleation. 26, 27 MiRNA expression profiling of hearts between postnatal days 1 and 10 has revealed that miR-195 is upregulated during this period, and premature overexpression of miR-195 in the embryonic heart causes a spectrum of congenital heart defects associated with premature cell-cycle arrest. Consistent with this, postnatal inhibition of the miR-15 family was associated with an increased number of mitotic cardiomyocytes, suggesting that miR-15 is antiproliferative in cardiomyocytes.
Porrello et al 28 recently found that neonatal hearts could regenerate after MI. Permanent ligation of left anterior descending coronary artery of 1-day-old mice has resulted in death of 75% of the myocardium by 72 hours. Further analysis has revealed a progressive regeneration of the anterior wall of the infarcted heart during a period 3 weeks, a response that was not noted in 7-or 14-day mice. However, neonatal mice overexpressing miR-195 (a member of the miR-15 family) specifically in the heart failed to invoke regenerative response after MI and displayed extensive fibrosis, suggesting a detrimental role of miR-195 in cardiac regeneration and MI. In line with this, inhibition of the miR-15 family increased adult cardiomyocyte proliferation and improved cardiac function after MI in adult animals. More recently, a study from Giacca's laboratory has reported that exogenous administration of certain miRNAs can stimulate cardiomyocyte proliferation. They found that miR-590-3p and miR-199a-3p promote cell-cycle re-entry of adult cardiomyocytes. Furthermore, after MI in mice, these miRNAs stimulated cardiac regeneration and restored cardiac function. 29 Effects of miR-590-3p on incorporation of an uridine analogue 5-ethynyl-29-deoxyuridine (an indicator of new DNA synthesis) by cardiomyocytes in the neonatal heart are depicted in Figure 1B .
Role of miRNAs in Cardiac Hypertrophy and Failure
The cardiovascular developmental roles and functions of miRNAs also helped to understand their pathophysiolgcal role in HF which is an end result of many factors including alterations in gene expression, myocyte and nonmyocyte growth, survival, and function. In view of the myriad biological functions mediated by miRNAs, it is not surprising that miRNAs also play important roles in various pathological conditions. According to a manually curated database of miRNAs and associated disease conditions (http://www.mir2disease.org/), there are ≥349 miRNAs that have experimentally validated roles in >160 disease conditions (database accessed on December 10, 2012). Clinical studies in human hearts indicate that fetal gene expression program is reactivated in failing hearts 30, 31 resulting in, but not limited to, a switching of structural proteins from the adult to the fetal isoforms including a decrease in the fast-shortening-velocity isoform (α-MHC) coupled with an increase in the slow-shortening-velocity isoform (β-MHC). This contributes to the decreased contractile function in failing human ventricular myocardium. 30, 31 Similarly, transcriptome analysis of failing and fetal hearts revealed a striking similarity in miRNA expression; ≈85% of the deregulated miRNAs in failing hearts displayed similar expression pattern as in fetal heart, suggesting that reactivation of a fetal miRNA program may contribute to the gene expression pattern of failing hearts, which resembles fetal heart. 32 In Online Table I , we summarized all available data about the role of miRNAs in cardiac hypertrophy, remodeling, and HF.
Need and Limitation of miRNA Animal Models
Appropriateness of a reductionist approach where function of a gene is inferred from deletion or mutation in a particular gene has been questioned by many researchers on the ground that many of the biological processes are complex and many genes have redundant roles. Thus it is not surprising that there are differences in genetic versus pharmacological deletion models. Nevertheless, genetically modified animals are invaluable resources to understand the function of many genes, which is evident from the fact that it is estimated that function of >7000 genes was ascertained through genetically modified animal models as on 2005 33 and their immense role in biological research was recognized by the Nobel prize in physiology in 2007. Conventional procedures of gene knockout (KO) where a particular gene is ablated from the whole body have many limitations including possible embryonic or early postnatal lethality. Although this highlights its absolute requirement in embryonic development, function of that particular gene in postnatal stages cannot be studied. This limitation has been successfully addressed by generation of conditional and inducible KO or transgenic animals where gene expression can be controlled spatially and temporally.
Conditional KO animal generation typically involves crossing animals having target sequence flanked by loxP sequences (originally derived from bacteriophage p1) with animals expressing Cre recombinase (recognizes loxp sequences) in a tissue-specific manner finally resulting in a tissue-specific ablation of target genomic sequence. 34 In addition to these conventional procedures, advanced technologies have been developed where gene targeting can be achieved, for example, via the use of zinc finger nucleases (ZFNs). ZFNs are members of a group of eukaryotic transcription factors each characteristically binding to a specific 3 bp sequences of DNA. Specificity of ZFNs depends on a stretch of 30 amino acid residues in ZFNs. A unique DNA sequence can be recognized by strategically choosing 3 to 4 ZFNs and joining all of them to a catalytic domain of a restriction enzyme Fok1 finally leading to cleavage of any desired genomic sequence. ZFNs can be directly introduced in mRNA form into embryos at single cell stage, which will be then implanted into the foster mother.
Transcription activator-like (TAL) effector nucleases is another class of nucleases that can be engineered to recognize a unique genomic sequence. Similar to ZFNs, TAL effector nucleases are also fused to catalytic domain of Fok1 restriction enzyme that brings in cleavage of recognized sequence. TAL effectors are proteins secreted by certain type of plantinfecting bacteria. These effectors recognize DNA sequence via a central domain containing variable number of 34 aa residues, and each repeat recognizes 1 nucleotide. Therefore, it is possible to design TAL effectors strategically to recognize any particular genomic DNA stretch and fuse it to a nuclease (TAL effector nucleases). As final specificity comes from single nucleotides, they are more designable, which is an advantage compared with ZFNs (specificity comes from 3 nucleotides; see review by Doetschman and Azhar 35 for detailed information). However, such approaches are still waiting to be used in cardiovascular research. Table 1 provides a thorough list of genetically modified animal models that are used so far in cardiovascular research.
Heart/Muscle-Specific miRNAs
Tissue-specific expression of miRNAs was first described in 2002. 45 A few years later, Zhao et al 20 reported about myocyte-specific expression of miR-1 in cardiac and skeletal muscle and in the same year their laboratory pioneered the role of miR-1 in cardiac differentiation. 46 These studies together with studies in the cancer field prompted researchers to search more comprehensively for the role of miRNAs in cardiac diseases. In subsequent years, Olson's laboratory first described deregulated miRNA expression in 2 different animal models of cardiac hypertrophy and idiopathic endstage failing human hearts. 47 Later, the same group discovered that a miRNA-208, which is expressed from intron 27 of α-myosin gene, is required for stress-induced cardiac hypertrophy. For this study they created the first ever miRNA KO animal for cardiovascular studies. They found that miR-208 −/− mice show reduced cardiac hypertrophy in response to pressure overload, 14 highlighting that miR-208 could be an important target for cardiac hypertrophy. In later studies, similar results were also obtained by Callis et al 15 who found that miR-208a was sufficient to induce cardiac remodeling and modulate the expression of hypertrophy-associated genes including β-MHC. Conversely, genetic deletion of miR-208a resulted in decreased β-MHC expression and amelioration of cardiac hypertrophy.
Montgomery et al 48 subsequently reported that systemic delivery of miR-208a inhibitors prevented pathological myosin switching and cardiac remodeling while improving cardiac function and survival. Intriguingly, the same group has recently found that this heart-specific miR-208a regulates systemic energy homeostasis via regulating mediator complex 13 protein expression. 49 They found that cardiac-specific overexpression of mediator complex 13 or pharmacological inhibition of miR-208a in mice confers resistance to high-fat diet-induced obesity and improves systemic insulin sensitivity and glucose tolerance. These findings are especially important as they substantiate earlier findings of the metabolic competence of the heart 50 and show a role of the heart in systemic metabolic control and finally indicate miR-208a to be a potential therapeutic target for metabolic disorders.
The role of miRNAs in cardiac disease was reiterated by Sayed et al, 51 who found that miR-1 expression is downregulated during aortic constriction-induced cardiac hypertrophy. Similar results were obtained in a later study where researchers found decreased miR-1 expression in different models of cardiac hypertrophy and failure including transverse aortic constricted mice or transgenic mice with selective cardiac overexpression of a constitutively active form of the Akt kinase. 52 As mentioned in previous sections, miR-1 is probably one of the most abundant miRNA in heart. 17, 45 MiR-1 regulates transcripts of several key genes that include transcription factors, 20, 53 receptor ligands, 46 ,54 apoptosis regulators, and ion channels. 55, 56 Although miR-1 has been found to be overexpressed in individuals with coronary artery disease and to exacerbate arrhythmogenesis when overexpressed, 55, 57 the majority of the studies indicate that miR-1 plays a protective role against cardiac hypertrophy or HF by regulating several hypertrophy-associated genes including calmodulin 1, 2, Mef2a 53 insulin-like growth factor-1, insulin-like growth factor-1R, 58 and sodium-calcium exchanger 56 and is downregulated in patients with aortic stenosis 59 and acromegalyassociated cardiac hypertrophy. 51, 58 Cardiac hypertrophy and HF are associated with abnormal calcium handling. Excitation-contraction coupling starts when small amounts of Ca 2+ enter into the cellular sarcoplasm through L-type calcium channels that trigger opening of the sarcoplasmic reticulum (SR) Ca 2+ release channel (ryanodine receptor 2), leading to a sudden and massive Ca 2+ release from the of the SR lumen to the sarcoplasm (calcium-induced calcium release). This sudden escalation of cytosolic calcium concentration activates cardiac troponin C that triggers myofibril contraction. SR Ca 2+ -ATPase (SERCA2a) then clears cytosolic Ca 2+ by transporting it back to the SR lumen, resulting in muscle relaxation. 60 Expression and activity of SERCA2a are impaired in failing hearts, 61 and viral SERCA2a gene transfer to failing hearts improves cardiac function and reduces arrhythmias in vivo 62 and in patients. 63 MiR-1 expression is restored after correction of calcium handling by adenoviral SERCA2a gene therapy. 56 Target identification studies revealed that sodium-calcium exchanger, which is frequently found to be upregulated in heart diseases, is a target of miR-1. In a later study, researchers found that sodium-calcium exchanger is also targeted by miR-214 that plays a protective role against ischemia-reperfusion injury by attenuating Ca 2+ overload-induced cardiomyocyte death through repression of sodium-calcium exchanger and downstream effectors of Ca 2+ signaling. 64 MiR-24, which is expressed by several cell types including cardiomyocytes, disturbs calcium homeostasis by targeting Junctophilin-2 leading to a reduction in fractional shortening of cardiomyocytes. Thus, many of the miRNAs expressed in the heart regulate and fine-tune calcium homeostasis (Figure 2 ). MiR-133a, which is also a muscle-specific miRNA, originates from the same bicistronic transcript as miR-1 66 and likewise, is also downregulated in cardiac hypertrophy. Carè et al 52 for the first time used antagomiRs to inhibit endogenous expression of miRNAs in the heart. They found that in vitro overexpression of miR-133 or miR-1 inhibited cardiomyocyte hypertrophy, whereas suppression of miR-133 induced hypertrophy. Consistent with this, in vivo inhibition of miR-133 by antagomiRs caused marked and sustained cardiac hypertrophy. However, in contrast, adult mice with genetic deletion of miR-133a-1 and miR-133a-2 showed no evidence of cardiac hypertrophy but displayed dilated cardiomyopathy with ventricular wall thinning and fibrosis. 16 These differences may be partly attributed to the differences in constitutive deletion or temporal inhibition of miR-133. In a separate study, miR-133 (and miR-30c) was found to target connective tissue growth factor which is a key profibrotic agent, suggesting that these miRNAs may function to inhibit cardiac fibrosis. 67 MiRNA-499 is expressed from an intron within Myh7b with specific expression in the heart and slow skeletal muscles. van Rooij et al 23 found that miR-208 is essential for the expression of miR-499 along with its host gene. Transgenic overexpression of miR-499 in the heart has resulted in cardiac hypertrophy and interstitial fibrosis. 68 However, in a simultaneous study, Wang et al 69 found that miR-499 protects from MI, and miR-499-overexpressing mice are resistant to left ventricular remodeling after ischemia-reperfusion. Although reasons for this discrepancy are not clear, more recent studies 70 also reveal that cardiomyocyte-specific overexpression of miR-499 results in HF in a transgenic mouse model suggesting a pathological role of miR-499 in the heart.
Non-cardiomyocyte-Specific miRs
Initially, heart/muscle-specific miRNAs were more attractive candidates compared with others for studies to identify miRNAs associated with cardiac hypertrophy and failure. However, several nonmyocyte-specific miRNAs did also prove to be important regulators of cardiac diseases. Cardiac fibrosis is a general hallmark of cardiac hypertrophy and HF, 71 although it is still not clear whether fibrosis is only a secondary effect of cardiac hypertrophy. MiR-21 is predominantly expressed in cardiac fibroblasts when compared with other cell types of the heart. It is one of the most significantly upregulated miRNA during cardiac hypertrophy and yet not exclusively expressed in the muscle. Pharmacological inhibition of miR-21 with cholesterol-conjugated antagomiRs has been shown to protect against fibrosis development after pressure overload in the heart. 72, 73 Importantly, by inhibition of cardiac fibrosis, there were also significant inhibitory effects on the development of cardiac hypertrophy pointing to cardiac fibrosis also as an initiator rather than a pure bystander of cardiac hypertrophy. 72 The role of miR-21 in fibrosis was later confirmed in the heart 74, 75 but also other organs including lung, 76 kidney, 77, 78 and skeletal muscle. 79 However, antifibrotic effects of miR-21 antagonism with small (8-mer) locked nucleic acid (LNA)-based inhibitors or general genetic deletion were not seen in response to cardiac stress. 80 These differences could be attributed to different antagomiR chemistries used 73 or genetic compensatory mechanisms because of constitutive loss of miRs as observed in many studies.
Transforming growth factor-β upregulates miRNA-21 expression in various cell types and induces epithelial-tomesenchymal transition, which could be responsible for the profibrotic effects of transforming growth factor-β. 81 Similarly, miR-21 was also found to be involved in transforming growth factor-β-induced endothelial-to-mesenchymal transition during cardiac pressure overload, 81 suggesting that the role of miR-21 in fibrotic response is more complicated and is a cumulative response of its effects on various cell types. van Rooij et al 82 found that miR-29, whose expression is suppressed by transforming growth factor-β, targets a battery of genes that are involved in fibrosis, such as collagens, fibrillins, and elastin. In addition, they found that after MI, miR-29 is suppressed in areas adjacent to infarct that led to derepression of its profibrotic targets leading to a fibrotic response, suggesting that miR-29 acts as a fibrosis regulator. Antifibrotic effects of miR-29 were recently reiterated also in the kidney in recent studies. 83, 84 Next to cardiomyocyte and fibroblasts, the endothelial cell (EC) fraction is also important for cardiac hypertrophy responses and transition to HF. For instance, miR-126 expression was found to be more abundant in organs with high vascular component, such as heart, lung, and aorta. In-depth analyses revealed that it is encoded from second intron of an EC-specific gene Egfl7. 85 Deletion of miR-126 resulted in embryonic or perinatal lethality in 40% of the mice because of vascular abnormalities. Although unoperated hearts of surviving miR-126 KO mice are histologically indistinguishable from that of wild type mice, after MI, mutant mice showed more ventricular dilation, extensive fibrosis, and HF. 85 A recent study by Jakob et al 86 reported that loss of miR-126 in angiogenic early outgrowth cells and CD34 + cells may limit cardiac neovascularization in chronic HF patients, demonstrating clinical importance of this miRNA. In another study, Bonauer et al 87 found that forced overexpression of miR-92a (a member of miR-17-92 cluster) suppressed in vitro and in vivo angiogenesis and inhibition of miR-92a enhanced cardiac recovery after acute MI. Another EC-enriched miRNA, miR-24, is upregulated in cardiac ischemia, induces EC apoptosis, and inhibits capillary network formation. Importantly, overexpression of miR-24 resulted in impaired angiogenesis in zebrafish and miR-24 inhibition led to improved vascularity, a decrease in infarct size and improved cardiac function. 88 Another group showed in vivo silencing of miR-24 by a specific antagomir in an aorta-constricted mouse model to prevent the degradation of heart contraction effectively but not ventricular hypertrophy by preventing decrease of L-type calcium channels. 89 MiR-210, which is increased in cardiomyocyte after hypoxia, exerts proangiogenic effects by inducing secretion of leptin, TNF-α, and interleukin-1α. In addition, intramyocardial injection of minicircle vectors carrying miR-210 resulted in significant improvement of left ventricular fractional shortening in a mouse model of MI. 90 These studies highlight the importance of EC-related miRNAs in cardiac function and pathology especially in the development of HF.
MiRNA-Mediated Regulation of Calcineurin/Nuclear Factor of Activated T Cells Signaling
Calcineurin (CN) is a ubiquitously expressed Ca 2+ -calmodulin-activated serine/threonine phosphatase that transduces Ca 2+ -dependent signaling events. In cardiomyocytes, CN dephosphorylates the nuclear factor of activated T cells (NFAT), which is otherwise kept in phosphorylated from by its inhibitory kinases such as dual specificity tyrosine phosphorylation-regulated kinase 1a (Dyrk1a), Dyrk2, glycogen synthase kinase 3, and casein kinase (Figure 2 ). Dephosphorylated NFAT translocates from the cytosol to the nucleus and transactivates hypertrophy-associated gene program. MiR-23a is a prohypertrophic miRNA that is transactivated by NFATc3 after hypertrophic stimulus. Elevated miR-23a expression leads to downregulation of its target muscle-specific ring finger 1 (Murf1), which is an antihypertrophic protein. 91 In another study, da Costa Martins et al 92 have found that miR-199b that is upregulated in mouse and human HF is transactivated by NFAT signaling. MiR-199b suppresses an NFAT inhibitory kinase Dyrk1a resulting in an auto-amplification loop. Transgenic mice overexpressing miR-199b are sensitized to CN/NFAT signaling or pressure overload and show stress-induced cardiac hypertrophy and HF. In vivo inhibition of miR-199b by antagomir administration normalized Dyrk1a expression, reduced NFAT activity, and caused a marked reversal of hypertrophy and fibrosis in a murine model.
Gurha et al 93 recently found that cardiomyocytes of miR-22 KO mice show reduced SR Ca 2+ load and reduced SERCA2a transporting activity. Deletion of miR-22 accelerated the progression to cardiac dysfunction and maladaptation during pressure overload and impaired SERCA2 expression/activity. Global transcriptome analysis has revealed that miR-22 targets Purb, which represses myocyte protein expression by binding to repressive purine nucleotide-rich elements (GGN) n . Incidentally, they found that many downregulated genes in miR-22 KO animals, including SERCA2a, had purine nucleotide-rich elements, which could be responsible for decreased expression of SERCA2a on miR-22 deletion. 93 However, other reports show a prohypertrophic effect of the overexpression of miR-22 94 ; thus, the exact function of this miRNA in cardiac hypertrophy and HF remains to be clarified.
MiR-132 and miR-212 are more ubiquitously expressed miRNAs and are processed from a bicistronic transcript. In a recent study, Ucar et al 95 have found that these miRNAs are upregulated after cardiac stress, and transgenic overexpression of these miRNAs specifically in cardiomyocytes induces extensive cardiac hypertrophy. Importantly, these 2 miRNAs target the antihypertrophic and proautophagic transcription factor forkhead box O3 and indeed significantly stimulated the CN-NFAT signaling pathway and, on the other hand, blocked autophagy responses in cardiomyocytes, thus resulting in an exaggeration of cardiomyocyte hypertrophy. In line with this, genetic deletion or pharmacological silencing protected against pressure-overload-induced HF, suggesting an essential role of these miRNAs for cardiac hypertrophy.
Diagnostic Use of Circulating miRNAs in Cardiac Hypertrophy and Failure
Earliest report of the existence of extracellular nucleic acids in the circulation dates back to 1948. 96 This observation is particularly remarkable because it was made only a few years after the discovery that DNA is the material of inheritance, even before the revolutionary article of Watson and Crick on DNA double-helical structure. By late 1990s, strong evidence has been provided that DNA in plasma or serum could be used as biomarkers for certain types of cancers. These findings prompted researchers to search for RNAs in the circulation, which led to identification of tumor-derived RNA in plasma samples. 97, 98 Existence of miRNAs in plasma or serum samples was first reported in 2008. 99, 100 Interestingly, circulating miRNAs have many of the essential characteristics of good biomarkers; they are highly stable and resistant to pH variations, longterm storage at room temperature, and repeated freeze-thaw cycles. 99, 100 More importantly, their levels can be specifically detected. Circulating miRNAs are packaged in microvesicles, exosomes, or associated with RNA-binding proteins, such as Ago2 (Figure 3) , which is primarily responsible for their enhanced stability. [101] [102] [103] However, the origin of these miRNAs is not completely ascertained; their occurrence in plasma/serum maybe the result of dead cells inside a tissue, or secretion by certain cells in response to a stimulus 104 ( Figure 3 ) or they may be derived from blood cells. 105 However, the latter is not an exclusive possibility because certain miRNAs in circulation, such as miR-206, miR-208, and miR-499, are not known to be expressed by any blood cells.
Although circulating miRNAs seem to be interesting candidates as cardiovascular biomarkers, at the moment they are not reported to have a superior role when compared with the classical biomarkers as they also posses several limitations, such as (1) they are generally present in low amounts in body fluids, such as plasma and serum, which may result in strong variations, and (2) at the moment there is no good natural stable housekeeping control for circulating miRNAs. Currently, researchers mainly use spiked in Caenorhabditis elegans miRNAs as internal controls. However, the stability of these externally added miRNAs is questioned. Some researchers suggest that circulating miRNAs do not require an internal control when equal volumes of plasma or serum are sampled as the volume of plasma or serum is clinical standard for other biomarkers.
The biggest limitation for use of miRNAs as biomarkers today is that the majority of the studies are performed in a small number of patients. Validation of candidate miRNAs in a bigger patient cohort and comparison with conventional HF biomarkers is important before they are recognized as clinically useful biomarkers. 106 Another level of complexity about the use of miRNAs as biomarkers is the effect of certain medications on the level of circulating miRNAs; levels of certain miRNAs, such as miR-126, was shown to be highly vulnerable to antiplatelet medications, such as aspirin and maybe many others. 107, 108 One of the most frequently identified circulating miRNAs to be increased in human and murine HF is miR-423_5p, [109] [110] [111] although others did not find an increase in other forms of HF 112 or association with cardiac remodeling processes after MI. 113 In the latter study, Bauters et al 113 included 246 wellcharacterized patients with MI and performed serial echocardiographic studies at different time intervals during a period of 1 year from hospital discharge. Circulating miR-133a and miR-423-5p levels in those patients were measured at all those time points. Although time-dependant changes were observed in miRNA levels, neither miR-133a nor miR-423-5p was associated with brain natriuretic peptide, indices of left ventricle function, and remodeling at any time point during 1 year after MI, reiterating the importance of larger patient numbers in biomarker studies and the need for more global miRNA approaches including sequencing data and miRNA network analyses to identify suitable biomarkers for HF and cardiac remodeling. An excellent review on the potential of miRNAs as biomarkers has been recently published. 114 Therefore, without going overly into details of each study, we summarized all the miRNA biomarker studies that are reported so far in cardiovascular field in Table 2 .
MiRNA Therapeutic Approaches for Cardiac Hypertrophy and HF
According to Office for National Statistics, cardiovascular diseases account for 32% of total deaths in England in 2010. Similarly, in the United States, cardiovascular diseases are the leading cause of death. According to the World Health Organization (WHO) estimations, 17.3 million people (accounting to 30% of total deaths) died because of cardiovascular diseases in the year 2008 alone. This threatening burden of mortality emphasizes the importance of thorough understanding of the diseases process at molecular level to proactively prevent death. Recent studies have highlighted the role of miRNAs as potential therapeutic targets in various disease conditions. 131, 132 In addition to cardiovascular diseases as outlined in previous sections, miRNAs play crucial role in pathophysiology of many other diseases including cancer, diabetes mellitus, obesity, viral infections, neurodegenerative diseases, hearing loss, drug addiction, etc, which prompted many pharmaceutical companies to invest largely in regulatory RNA-based therapeutic developments. 133 As a result, within 10 years of experimental validation of the first miRNA, an miRNA-based therapeutic has already entered phase II clinical trials (http://www. clinicaltrials.gov/ ct2/show/NCT00980161). As outlined in previous sections, miRNAs have beneficial and detrimental effects on the heart (Figure 4) . MiRNA therapeutics can be broadly categorized as (1) miRNA mimics to regain the expression of suppressed ACS indicates acute coronary syndrome; AMI, acute myocardial infarction; CMR, cardiovascular magnetic resonance; CHF, chronic heart failure; ESRD, end-stage renal disease; HF, heart failure; LV, left ventricle; MI, myocardial infarction; miR/miRNA, microRNAs; NSTEMI, non-ST-segment-elevation myocardial infarction; NYHA, New York Heart Association; and STEMI, ST-segment-elevation myocardial infarction. miRNAs (replacement therapy) and (2) miRNA inhibitors to inhibit endogenous miRNAs that show enhanced expression during disease. In the majority of the settings, when modulation of miRNA expression in vivo is concerned, more approaches to inhibit an upregulated miRNA than overexpress a downregulated one have been performed (Table 1) .
Cholesterol and LNA-Based miR Inhibitors
Silencing of the miRNAs using miRNA antagonists using cholesterol conjugation (termed antagomiRs) was first reported by Krützfeldt et al. 134 AntagomiRs are modified antisense oligonucleotides having the full or partial complementary sequence of a mature miRNA that can reduce the endogenous levels of a miRNA. Various chemical modifications have been suggested to improve the cellular uptake, stability, and binding efficacy of the antagomiRs. These modifications mainly include 2-O-methyl-and LNA modifications where the 2-oxygen of a nucleotide is connected to the 4-position by a methylene linker resulting in a rigid bicycle locked into a C3-endo (RNA) sugar conformation. 135, 136 After the first report of successful knockdown of endogenous miRNAs after intravenous injection of cholesterol-conjugated antagomiRs 134 Carè et al 52 used a similar approach to silence miR-133, which resulted in cardiac hypertrophy in a murine model. This was then followed by several reports of successful pharmacological knockdown of many miRNAs. 132 Latter studies indicated that LNA modification is more superior than cholesterol conjugation as it results in a thermodynamically stronger duplex formation with the target RNA 137 and, therefore, may be more effective. Inhibitors of miR-122 that are now being tested in clinical trials are also based on LNA chemistry. As a further development to ≈22 nt long LNA oligos, shorter versions of LNA oligos which are 8 nt long have been reported. 80, 138 Their shorter size allows knockdown of all miRNAs belonging to a particular family sharing same seed sequence. For example, members of miR-30 or miR-132 family share same seed sequence, in such instances it is sufficient to just use a single oligonucleotide species. However, caution should be taken as pharmacokinetics of 8-mer oligonucleotides is different from 22-nt long oligonucleotides that may result in differential action in some organs. 73 
miRNA Sponges
Another innovative, but comparatively less widely used technology so far is miRNA sponges. 139 
Adeno-Associated Virus Vectors
In an in vitro setting, particular miRNA expression can be induced by transfecting cells with specific synthetic RNA duplexes. The same is also possible in animals, at least theoretically. Exogenous RNA duplexes that are chemically modified to enhance cellular uptake and stability can be administered via selected route to enhance expression of a particular miRNA. However, as the delivery to the target organ is not controlled and higher possibility of off-target effects limits this kind of approach. Discovery of tissue-specific tropism of different adeno-associated virus (AAV) serotypes and low immunogenicity of AAV presents an attractive approach to limit the uptake of miRNA coding sequences to a specific tissue of interest. Bish et al 141 reported a superior cardiac-specific gene delivery that is stable for ≥1 year using AAV9 vectors. Altogether, these results suggest that AAV-mediated gene delivery approaches may be effective for cardiac diseases. Some of the miRNAs have already been overexpressed in the heart in animal models using AAV vectors (Table 1) .
Aptamers and Nanoparticles
Aptamers are the molecules that bind to specific molecule or cells. Nucleic acid aptamers recognizing a specific molecule or cell are engineered by repeated rounds of selection procedure called systematic evolution of ligands by exponential enrichment. It is possible to conjugate miRNAs or shRNAs to engineered aptamer to be specifically delivered to a cell type. 142 However, such approach still waits to be used in cardiovascular research. In a more recent study, researchers found that systemic administration of cationic lipid-based nanoparticle encapsulating premiR-107 inhibited tumor growth in a head and neck squamous cell carcinoma model. 143 Similar to aptamers, nanoparticles can be engineered to recognize certain cell types, for example, by coating with antibodies against surface proteins expressed by that particular cell type. One such entity is currently being tested in clinical trials for metastatic cancer (http://clinicaltrials.gov/show/ NCT01300533). Although cell-specific nanoparticles are not yet tested in heart research, these strategies will certainly help development of tissue-specific or cell-type-specific delivery of miRNAs in the heart. Although safety of certain miRNA therapies has been already tested in human subjects, great care needs to be taken to oligonucleotide-specific or oligonucleotide-unspecific side effects that may occur systemically or in an organ-specific manner (eg, hepatotoxicity or kidney toxicity). Further delivery strategies include miR-1, miR-101, miR-133,  miR-142, miR-144/451,  miR-145, miR-17, miR-18,  miR-19, miR-210, miR-214,  miR-30, miR-494 polyethylenimine-mediated delivery (eg, miR-145 and miR33a inhibited tumor growth in a colon carcinoma model). 144 An Outlook: lncRNAs in the Cardiovascular System
Because of rapidly developing technologies, it is now possible to screen thousands of miRNAs across the genomes under different conditions. This rapid growth in technology has enabled researchers to identify miRNAs that are crucial for onset and progression of various disease conditions. MiRNAs are now widely accepted as potential targets in cardiovascular diseases. However, efficacy of these new classes of pharmacological agents over the classical therapeutic modalities has to be tested thoroughly in large animal models. It is anticipated that miRNA modulators will be available as therapeutic options in a not too far future. Moreover, miRNAs have a huge potential as biomarkers for various cardiovascular diseases. However, it needs more endeavor and stringent analyses before they are appreciated and widely used as clinically important biomarkers for cardiovascular diseases. The identification of miRNAs to be expressed within and to be key regulators of the human genome was a fundamental finding that is still to be explored. Often during discovery of new galaxies, more surprises occur. Indeed, whereas the human genome is much larger than that of more simple organisms such as worms, it has a comparable number of protein-regulating genes. For instance, the genome of 959-cell bodied C elegans and 100 000 billion-cell bodied humans typically contain a similar number of protein-coding genes and yet the human genome is 30× bigger than the C elegans genome (100 MB versus 3000 MB).
We are just about to explore this dark matter of the genome and a new star that appeared is further longer ncRNAs. These transcribed sequences of long (>200 bp) ncRNAs (lncRNAs) seem to function as an additional regulatory machinery of the genome controlling both transcriptional and post-transcriptional events. 145 In contrast to the growing knowledge in miRNAs, less is known about the cardiovascular functions of lncRNAs. One recent example is the key role of the lncRNA, Braveheart, that is necessary for activation of a core cardiovascular gene network and functions upstream of mesoderm posterior 1, a master regulator of a common multipotent cardiovascular progenitors. 3 This lncRNA also mediated epigenetic regulation of cardiac commitment is important for the maintenance of the cardiac fate in neonatal cardiomyocytes. This first description of the critical regulatory role of a lncRNA in the establishment of the cardiovascular lineage during mammalian development will be followed by further insight about the role of lncRNAs in the complex galaxy of regulatory RNAs in the cardiovascular system. LncRNAs may help us not only to better understand epigenetic mechanisms, but also finally to develop therapeutic targeting strategies or use of circulating lncRNAs as novel biomarkers of cardiovascular diseases.
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